SCHEMBL4882115

SCHEMBL4882115

OC(CNC1C2CNCC21)C(O)(c1ccccc1)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SSTR4 P31391 2/20 0.39
MAN2A1 Q16706 1/20 0.38
MAN1B1 Q9UKM7 1/20 0.38
LMNA P02545 2/20 0.33
CYP2D6 P10635 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
HRH1 P35367 1/20 0.33
SCN1A P35498 1/20 0.33
SCN2A Q99250 1/20 0.33
SCN3A Q9NY46 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP2C19 P33261 1/20 0.33
HSD17B10 Q99714 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPK1 P28482 1/20 0.33
TTR P02766 1/20 0.32
SLC6A2 P23975 1/20 0.32
MC4R P32245 1/20 0.31
PRMT5 O14744 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4880745 0.82 MEN1 (0.38) SSTR4LMNACYP2D6MEN1KMT2A
SCHEMBL4882920 0.78 FUCA1 (0.41)
SCHEMBL5948255 0.67 CHRM2 (0.49) SSTR4LMNACHRM3
SCHEMBL4924718 0.66 HRH2 (0.53) SSTR4MEN1KMT2AALDH1A1MC4R
SCHEMBL4909653 0.66 SSTR4 (0.39) SSTR4MEN1KMT2AALDH1A1KDM4E
SCHEMBL4883020 0.65 BCHE (0.59) MEN1KMT2AALDH1A1KDM4EMAPK1
SCHEMBL27906586 0.65 CYP2C19 (0.46) LMNACYP2D6MEN1KMT2AALDH1A1
SCHEMBL416117 0.63 GRIN1 (0.50) LMNACYP2D6MEN1KMT2AALDH1A1
SCHEMBL5948018 0.63 CHRM2 (0.49) CHRM3
SCHEMBL5948016 0.63 CHRM2 (0.49) CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080280883-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-11-13 US claimed
US-20080280883-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-11-13 US disclosed
EP-1794161-A2 MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2007-06-13 EP disclosed
WO-2006032994-A2 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280883-A1 Muscarinic Receptor Antagonists CHRM3, CHRM5, CHRM2 SSTR4 478/4885MAN2A1 805/4885MAN1B1 674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.